Technical Analysis for IPSC - Century Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 2.98 | 4.75% | 0.14 |
IPSC closed up 4.75 percent on Thursday, April 18, 2024, on 67 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 200 DMA | Bullish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Fell Below 200 DMA | Bearish | 4.75% | |
| Lower Bollinger Band Walk | Weakness | 4.75% | |
| Stochastic Reached Oversold | Weakness | 4.75% | |
| Wide Bands | Range Expansion | 4.75% |
| Alert | Time |
|---|---|
| Possible NR7 | about 12 hours ago |
| 200 DMA Resistance | about 14 hours ago |
| Up 5% | about 15 hours ago |
| Rose Above 200 DMA | about 15 hours ago |
| Up 3% | about 15 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/13/2024
Century Therapeutics is harnessing the power of adult stem cells to develop curative cell therapy products for cancer that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived iNK and iT cell products are designed to specifically target hematologic and solid tumor cancers. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provides an opportunity to advance the course of cancer care.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Life Sciences Biology Stem Cell Cell Therapy Cell Biology Cancer Care Induced Stem Cells Cloning
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Life Sciences Biology Stem Cell Cell Therapy Cell Biology Cancer Care Induced Stem Cells Cloning
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 5.51 |
| 52 Week Low | 1.28 |
| Average Volume | 217,678 |
| 200-Day Moving Average | 2.94 |
| 50-Day Moving Average | 4.22 |
| 20-Day Moving Average | 3.83 |
| 10-Day Moving Average | 3.58 |
| Average True Range | 0.40 |
| RSI (14) | 34.21 |
| ADX | 15.08 |
| +DI | 17.22 |
| -DI | 29.85 |
| Chandelier Exit (Long, 3 ATRs) | 4.04 |
| Chandelier Exit (Short, 3 ATRs) | 3.95 |
| Upper Bollinger Bands | 4.73 |
| Lower Bollinger Band | 2.93 |
| Percent B (%b) | 0.03 |
| BandWidth | 47.17 |
| MACD Line | -0.31 |
| MACD Signal Line | -0.20 |
| MACD Histogram | -0.1053 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.43 | ||||
| Resistance 3 (R3) | 3.40 | 3.23 | 3.35 | ||
| Resistance 2 (R2) | 3.23 | 3.11 | 3.24 | 3.32 | |
| Resistance 1 (R1) | 3.10 | 3.04 | 3.16 | 3.13 | 3.30 |
| Pivot Point | 2.93 | 2.93 | 2.96 | 2.94 | 2.93 |
| Support 1 (S1) | 2.80 | 2.81 | 2.86 | 2.83 | 2.65 |
| Support 2 (S2) | 2.63 | 2.74 | 2.64 | 2.63 | |
| Support 3 (S3) | 2.50 | 2.63 | 2.60 | ||
| Support 4 (S4) | 2.53 |
